Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Zika Not Likely to Affect Large Parts of U.S., Medical Geographer Says

By Drug Discovery Trends Editor | February 1, 2016

There’s no reason to suspect Zika will be much different from dengue fever, and those outbreaks in the United States have been pretty locally contained, according to Jared Aldstadt, University at Buffalo associate professor of geography in the College of Arts and Sciences.
 
Aldstadt’s research focuses on the mosquito species that transmits Zika, dengue fever, yellow fever and chikungunya.
 
“If you live in parts of Hawaii, Key West or on the U.S.-Mexico border, it’s a concern because of the nature of the mosquito, but this is not something that is going to affect large parts of the country,” he says. “This is something the U.S. can handle. Zika is limited by the mosquito and we are well protected with air conditioning and our well-built buildings.
 
“There is no evidence Zika will be different than dengue when it arrives occasionally in the U.S. and circulates locally for a while.”
 
Researchers are still gathering evidence about the link between Zika and microcephaly, Aldstadt says.
 
“Several infections are risk factors for birth defects,” he says. “There’s a chance that other infections are happening, too. There are a lot of other alternatives when it comes to microcephaly.”
 
While Aldstadt is in agreement with a travel advisory for pregnant women to be safe, there could be other risk factors at play, he says.
 
The mosquito that transmits Zika is a domesticated one that lives in clean water, Aldstadt says. It is not usually found in the natural environment. It was a major concern during the construction of the Panama Canal because of yellow fever, and was eradicated from much of tropical America in the 1950s.
 
“A place like Brazil is a perfect breeding ground for the mosquito because of the rapid urbanization and the often poor-quality housing,” he says. “The risk declines significantly at the U.S. border because the better housing quality and air conditioning protects people.”
 
Right now, places such as Brazil should be spraying indoors where the mosquitoes live, as well as removing breeding sites, such as water-holding containers, trash, tires and flower pots, Aldstadt says.
 
“People can protect themselves by wearing long sleeves and pants and can also use insecticide treatment,” he says.
 
Source: University at Buffalo

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE